Russian drug manufacturer begins trials of cancer medication analog
A Russian pharmaceutical company has commenced clinical trials for a new medicinal drug. The goal of the trials is to prove the bioequivalence of the Russian product to the original foreign drug "Xalkori," which is used for the treatment of oncological diseases.
"Xalkori," developed by Pfizer, is a targeted therapy drug. This means that it acts directly on cancer cells, blocking their growth. Such medications play an important role in modern medicine, helping patients fight severe forms of the disease.
During the current studies, specialists are comparing the new Russian drug with the original. Scientists are verifying how effectively and safely the domestic analog acts. If the test results are successful, it will allow for the registration of the drug and make it more accessible to Russian patients.
Creating domestic analogs of imported drugs is an important step toward ensuring the country's pharmaceutical security. The emergence of generics—drugs with the same active ingredient as the original—helps reduce the cost of treatment and expand the capabilities of the healthcare system.
At the moment, the company is continuing to collect data necessary to confirm the quality of the drug. It is expected that after the completion of all trial stages and the receipt of the relevant permits, the new medication will be able to enter pharmacies and medical institutions in Russia.